Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
MWN-AI** Summary
Keros Therapeutics, Inc. has announced a significant collaboration with the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) to evaluate the therapeutic potential of rinvatercept in patients with amyotrophic lateral sclerosis (ALS). This partnership comes as part of the Healey ALS MyMatch program, a pioneering initiative aimed at accelerating ALS therapy development by utilizing biomarker-driven personalized approaches. The integration of genetic and biofluid markers will allow for precise matching of ALS patients to suitable experimental treatments, enhancing the likelihood of successful outcomes.
Keros, a clinical-stage biopharmaceutical company focused on innovative therapies related to the transforming growth factor-beta (TGF-ß) protein family, believes rinvatercept has a strong scientific basis for potentially preserving muscle strength and function in ALS patients. Dr. Jasbir S. Seehra, Keros’ CEO, expressed pride in collaborating with the Healey Center, highlighting the urgency for new ALS treatment options.
The Healey ALS MyMatch program includes multiple research centers and aims to deepen the understanding of experimental products while identifying optimal patient populations for future trials. Additionally, the collaboration aligns with Keros’ commitment to developing therapeutic strategies that can provide significant benefits in muscle regeneration and strength, as rinvatercept is designed to inhibit negative regulators of muscle and bone mass.
Dr. Merit Cudkowicz, director of the Healey Center, underscored the importance of new treatment options for ALS patients in light of the disorder's devastating nature. The partnership marks a crucial step towards potentially transforming the landscape of ALS treatment through innovative research strategies. This initiative exemplifies the collaborative efforts necessary to expedite the discovery and development of therapies for one of medicine's most challenging diseases.
MWN-AI** Analysis
Keros Therapeutics' recent collaboration with the Sean M. Healey & AMG Center for ALS is a significant development for the company and warrants a closer look for potential investors. This partnership aims to advance the evaluation of rinvatercept in treating amyotrophic lateral sclerosis (ALS) through the ALS MyMatch program, which utilizes a biomarker-driven approach to optimize clinical trial efficiency.
The backdrop of this initiative is especially timely given the urgent need for effective treatments in a condition that has historically seen limited therapeutic options. Keros Therapeutics positions rinvatercept as a potentially innovative therapy that targets muscle regeneration and may impact patient quality of life positively. The participation in the ALS MyMatch program underscores the credibility of Keros' research direction and its synchronization with broader efforts to expedite ALS therapy development.
From a market perspective, Keros (Nasdaq: KROS) presents an intriguing investment opportunity. As a clinical-stage biopharmaceutical company, its success largely hinges on the progress and outcomes of its clinical trials. The partnership with a reputable institution like Massachusetts General Hospital adds a layer of validation and may bolster investor confidence. Moreover, the integration of advanced biomarker methodologies could refine patient selection, potentially increasing the trial's success rates and preparing the pathway for later-stage approvals.
However, investors must remain mindful of the inherent risks associated with clinical trials, particularly in a competitive field such as ALS treatment development. Challenges related to funding, trial enrollment, and regulatory approval can impact Keros’ trajectory.
In summary, while Keros Therapeutics shows promise driven by its collaboration and innovative approach, investors should carefully weigh potential rewards against the operational risks and market uncertainties inherent in the biopharmaceutical sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it has entered into an agreement with the Massachusetts General Hospital (“MGH”) for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis (“ALS”) within the Healey ALS MyMatch program (“ALS MyMatch”), led by the Sean M. Healey & AMG Center for ALS at Mass General Brigham.
The collaboration is in response to the Healey & AMG Center’s call for applications for the ALS MyMatch program. The ALS MyMatch program is accelerating the development of new therapies for ALS by harnessing the power of biomarker-driven personalized trial approaches. By integrating comprehensive genetic and biofluid markers, the program matches subgroups of ALS individuals to various experimental therapies based on their disease markers. ALS MyMatch is an ongoing series of early-stage Phase 1b/2a clinical trials aimed at deepening the understanding of biological effects of experimental products and identifying the optimal population for future later-stage Phase 2/3 clinical trials.
“We are proud to be selected to the ALS MyMatch program to collaborate with the Healey & AMG Center at Mass General,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. “Rinvatercept represents a potentially novel approach to treat patients with ALS. Based on the data we have generated to date, we believe there is a strong scientific rationale for the potential of rinvatercept to preserve muscle strength and function and improve quality of life in patients with ALS.”
“ALS is a serious, progressive disorder with need of additional treatment options,” said Merit Cudkowicz, M.D., M.Sc., director of the Sean M. Healey & AMG Center for ALS, executive director of the Neuroscience Institute at Mass General Brigham, and the Julieanne Dorn Professor of Neurology at Harvard Medical School. “We look forward to partnering with Keros to evaluate rinvatercept within the ALS MyMatch program, bringing us closer to our goal of finding additional treatments for those battling ALS.”
About Healey ALS MyMatch
Healey ALS MyMatch is a multi-site, collaborative initiative that currently brings together four trial-ready, high enrolling ALS research centers and is a Network of Excellence for ALS (NEALS) affiliated program. Research centers include Mass General in Boston; University of Minnesota in Minneapolis, Minn.; Northwestern University in Evanston, Ill.; and Nova Southeastern University in Fort Lauderdale, Fla. ALS MyMatch has partnered with the Acceleration Centers of Enrollment (ACE) program, a community-driven philanthropic partnership program focused on expediting start up and recruitment at study centers. Additional trials and high performing sites will be added as the program grows.
About the Sean M. Healey & AMG Center for ALS at Mass General Brigham
The Sean M. Healey & AMG Center for ALS at Mass General Brigham, launched in 2018, brings together a global network of scientists, physicians, nurses, foundations, federal agencies and people living with ALS, their loved ones, and caregivers to accelerate the pace of ALS therapy discovery and development.
About Rinvatercept
Rinvatercept is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB that is fused to the portion of the human antibody known as the Fc domain. Rinvatercept is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A, which are negative regulators of muscle and bone mass and strength, to improve skeletal muscle regeneration, increase muscle size and strength, inhibit and reduce fibrosis, inhibit inflammation, reduce fat accumulation and improve bone health through bone anabolic mechanisms. We are developing rinvatercept for the treatment of Duchenne muscular dystrophy and for the treatment of ALS.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of Duchenne muscular dystrophy and for the treatment of ALS. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “believe,” “forward,” “goal,” “potential” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: the potential of rinvatercept to preserve muscle strength and function and improve quality of life in patients with ALS. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K, filed with the SEC on March 4, 2026, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contacts
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
Media Contact:
Mahmoud Siddig / Adam Pollack / Viveca Tress
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
FAQ**
How does the partnership between Keros Therapeutics Inc. KROS and the Healey ALS MyMatch program potentially impact the clinical development timeline for rinvatercept in ALS patients?
What specific biomarkers will Keros Therapeutics Inc. KROS utilize in the ALS MyMatch program to identify patient subgroups for rinvatercept treatment?
Given the competitive landscape, how does Keros Therapeutics Inc. KROS plan to differentiate rinvatercept from other potential therapies for ALS?
What are the key milestones that Keros Therapeutics Inc. KROS aims to achieve in the development of rinvatercept through the ALS MyMatch program?
**MWN-AI FAQ is based on asking OpenAI questions about Keros Therapeutics Inc. (NASDAQ: KROS).
NASDAQ: KROS
KROS Trading
3.6% G/L:
$11.21 Last:
331,187 Volume:
$10.95 Open:
